Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Harvard Bioscience Q1 2026 Earnings Call - NPI Revenue Surge Offsets Academic Slowdown
Harvard Bioscience delivered Q1 2026 revenue of $20.8 million, perfectly aligning with guidance despite a year-over-year decline driven by a thawing academic sector in the Americas and APAC distributo...
- Q1 2026 revenue came in at $20.8 million, exactly in line with the $20 million to $22 million guidance range.
- New product innovation (NPI) revenue, led by Mesh MEA, BTX, and SoHo, grew to over 12% of total revenue, up from approximately 4% in Q1 2025.
- Adjusted gross margin expanded 300 basis points year-over-year to 59%, benefiting from cost actions and a higher mix of high-margin NPI products.
- +9 more takeaways
Sanara MedTech Q1 2026 Earnings Call - Pure-Play Surgical Focus Drives First GAAP Profitability
Sanara MedTech delivered its first GAAP profitable quarter as a pure-play surgical company, with Q1 2026 revenue jumping 19% year-over-year to $27.8 million. The company logged $0.4 million in net inc...
- Sanara MedTech achieved its first GAAP net profitability as a pure-play surgical company, reporting $0.4 million in net income or $0.04 per diluted share for Q1 2026, a stark reversal from the $0.6 million loss in Q1 2025.
- Revenue surged 19% year-over-year to $27.8 million, outpacing expectations and driven primarily by increased sales of soft tissue repair products CellerateRX and BIASURGE.
- Gross margins expanded by 100 basis points to 93% of net revenue, reflecting favorable product mix, geographic expansion, and successful penetration into new hospital and ASC networks.
- +7 more takeaways
LightInTheBox Q1 2026 Earnings Call - Record Profit and Branded Apparel Surge Drive Turnaround
LightInTheBox delivered its eighth consecutive profitable quarter and a record first quarter profit of $1.2 million in Q1 2026, up from just $0.1 million in the same period last year. Revenue grew 11%...
- 1. LightInTheBox reported a record first quarter profit of $1.2 million in Q1 2026, a twelvefold increase from the $0.1 million profit in Q1 2025.
- 2. This marks the company’s eighth consecutive profitable quarter, signaling a sustained operational turnaround that began in 2025.
- 3. Total revenue grew 11% year-over-year to $52 million, representing the second consecutive quarter of top-line growth and returning to double-digit expansion.
- +7 more takeaways
Tencent Music Entertainment (TME) Q1 2026 Earnings Call - AI-Driven Piracy Threatens Core Streaming Growth as TME Pivots to IP-Centric Ecosystem
Tencent Music Entertainment reported 7% year-over-year revenue growth in Q1 2026, driven by a 12% jump in music services revenue and triple-digit growth in offline concert-related services. The compan...
- Revenue grew 7% year-over-year to RMB 6.0 billion, with music-related services up 12% year-over-year, driven by membership and offline performance growth.
- Membership revenue reached RMB 4.6 billion, up 7% year-over-year, though quarter-over-quarter results dipped slightly due to price-sensitive user churn on the Kugou platform.
- Offline concert-related services achieved triple-digit year-over-year growth, reinforcing TME’s pivot toward a holistic, IP-centric monetization model beyond traditional streaming.
- +7 more takeaways
Core Scientific Q1 2026 Earnings Call - $3.3B Financing Secured, Hyperscaler Demand Intensifies as CoreWeave Revenue Scales
Core Scientific delivered a decisive operational and financial update in Q1 2026, marking a pivotal shift from development to revenue generation. The company now bills for 243 MW of core data center c...
- Core Scientific closed a $3.3 billion project bond financing at a 7.75% interest rate, with net proceeds of approximately $2.9 billion to fund future growth and new customer projects.
- The company is now billing for 243 MW of billable capacity to CoreWeave, generating over $350 million in annualized GAAP colocation revenue, marking a significant transition to revenue generation.
- Core Scientific raised its target gross profit margin for the CoreWeave contract to 80-85%, up from the original 75-80%, reflecting improved cost visibility and execution experience.
- +7 more takeaways
DoorDash Q1 2026 Earnings Call - Best-of-Breed Execution Drives Share Gains Amidst AI Integration and Tech Re-platforming
DoorDash is doubling down on a 'best-of-breed' philosophy, leveraging AI and a global tech re-platforming to fortify its dominance in local commerce. Management emphasized that agentic AI and autonomo...
- DoorDash is pursuing a 'best-of-breed' strategy, focusing on end-to-end experience quality rather than just top-of-funnel traffic, to defend against AI intermediaries and competitors.
- Management views agentic AI as a tool to enhance discovery and ordering friction, not as a disintermediation risk, citing historical precedent where Google and Amazon failed to retain users despite top-of-funnel dominance.
- The global tech re-platforming is on schedule, with production traffic now live across DoorDash, Wolt, and Deliveroo, expected to improve feature velocity and allow cross-pollination of logistics innovations.
- +7 more takeaways
BillionToOne Q1 2026 Earnings Call - 84% Revenue Growth Paired with 16% GAAP Operating Margin
BillionToOne delivered a quarter that defies the typical high-growth narrative. Revenue surged 84% year-over-year to $108.4 million, driven by a 44% increase in test volume and a 28% jump in average s...
- Revenue surged 84% year-over-year to $108.4 million, with test volume growing 44% and ASPs rising 28% to $571 per test.
- BillionToOne achieved a 16% GAAP operating margin and 24% adjusted EBITDA margin, demonstrating rare profitability for a high-growth company.
- Full-year 2026 revenue guidance was raised to $450–$465 million, reflecting strong Q1 performance and expected ASP lifts from new payer contracts.
- +7 more takeaways
Chegg, Inc. Q1 2026 Earnings Call - AI-Driven Skilling Growth and Debt-Free Balance Sheet Signal Strategic Pivot
Chegg delivered a strong first quarter of 2026, exceeding expectations on revenue, profitability, and free cash flow while aggressively cutting costs and eliminating debt. The company’s pivot to an AI...
- Chegg exceeded Q1 2026 expectations across revenue, profitability, and free cash flow, signaling successful execution of its AI-first restructuring.
- Chegg Skilling revenue grew 9% year-over-year to $17.6 million, with management targeting double-digit growth for the full year and acceleration in H2.
- New enterprise partnerships, including Cornerstone and Woolf, provide scalable distribution channels for Chegg Skilling and accredited AI Master’s programs.
- +7 more takeaways
Wheaton Precious Metals Q1 2026 Earnings Call - Record Cash Flow and Historic $4.3B Antamina Silver Stream
Wheaton Precious Metals delivered a record-breaking first quarter of 2026, driven by surging gold equivalent prices and operational outperformance at Salobo and Penasquito. Revenue hit $901 million, n...
- Record Q1 2026 financial performance: Revenue of $901 million, net earnings of $582 million, and operating cash flow of $766 million, all representing year-over-year increases of over 90%.
- Historic Antamina transaction: Closed a $4.3 billion streaming agreement with BHP for 33.75% of silver production, the largest precious metal streaming deal in history and the largest in Wheaton’s portfolio.
- Production growth trajectory: Q1 attributable production of 212,000 GEOs, up 22% year-over-year. Full-year 2026 guidance remains 860,000 to 940,000 GEOs, with a long-term target of 1.2 million GEOs by 2030, reflecting a 50% CAGR.
- +7 more takeaways
ADMA Biologics Q1 2026 Earnings Call - ASCENIV Demand Surges Amid Standard IG Dislocation
ADMA Biologics reported a quarter of stark contrasts in Q1 2026, with total revenue flat year-over-year at $114.5 million while adjusted net income jumped 22% to $40.7 million. The divergence tells a ...
- Total revenue was flat year-over-year at $114.5 million, but adjusted net income surged 22% to $40.7 million, highlighting a sharp divergence between top-line stagnation and bottom-line expansion.
- ASCENIV revenue grew 28% year-over-year to $97.5 million, driven by record new patient starts, prescriber adoption, and strong product pull-through.
- BIVIGAM revenue collapsed 54% year-over-year to $15.4 million, disproportionately impacted by aggressive discounting and rebating from new entrants in the standard IG market.
- +7 more takeaways